Brokerages Set Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Price Target at $77.20

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) have received a consensus rating of “Buy” from the seventeen analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, fourteen have issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $77.20.

XENE has been the subject of a number of research analyst reports. Needham & Company LLC decreased their price objective on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a report on Friday, May 8th. JPMorgan Chase & Co. increased their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research report on Wednesday, May 27th. Royal Bank Of Canada raised their price target on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Monday, July 6th. Finally, Wells Fargo & Company reiterated an “overweight” rating and issued a $69.00 price objective on shares of Xenon Pharmaceuticals in a research note on Sunday, May 10th.

Insider Buying and Selling at Xenon Pharmaceuticals

In related news, Director Gillian Cannon sold 1,190 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the completion of the sale, the director owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. This trade represents a 44.99% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Gary Patou sold 1,322 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the sale, the director directly owned 24,896 shares in the company, valued at approximately $1,322,973.44. This trade represents a 5.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 2.91% of the company’s stock.

Institutional Trading of Xenon Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Avoro Capital Advisors LLC lifted its stake in shares of Xenon Pharmaceuticals by 0.5% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,424,444 shares of the biopharmaceutical company’s stock valued at $243,124,000 after buying an additional 24,444 shares in the last quarter. Janus Henderson Group PLC grew its stake in Xenon Pharmaceuticals by 2.3% in the 1st quarter. Janus Henderson Group PLC now owns 4,175,982 shares of the biopharmaceutical company’s stock valued at $242,858,000 after buying an additional 91,948 shares in the last quarter. Wellington Management Group LLP grew its stake in Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after buying an additional 1,435,096 shares in the last quarter. Capital International Investors raised its holdings in Xenon Pharmaceuticals by 7.3% during the 4th quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company’s stock valued at $153,058,000 after acquiring an additional 233,466 shares during the period. Finally, Commodore Capital LP raised its holdings in Xenon Pharmaceuticals by 30.1% during the 2nd quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock valued at $94,682,000 after acquiring an additional 700,000 shares during the period. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ:XENE opened at $65.42 on Monday. Xenon Pharmaceuticals has a 1 year low of $30.00 and a 1 year high of $72.66. The company has a market capitalization of $6.32 billion, a PE ratio of -13.92 and a beta of 0.61. The business has a fifty day moving average price of $58.30 and a two-hundred day moving average price of $52.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, hitting analysts’ consensus estimates of ($1.17). During the same period in the prior year, the firm earned ($0.83) EPS. Sell-side analysts anticipate that Xenon Pharmaceuticals will post -4.92 earnings per share for the current year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.